ADMA Biologics, Inc.
ADMA
$9.36
-$0.18-1.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 8.65% | -17.73% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 8.65% | -17.73% | |||
| Cost of Revenue | 12.97% | -32.98% | |||
| Gross Profit | 6.84% | -9.08% | |||
| SG&A Expenses | -0.15% | 12.85% | |||
| Depreciation & Amortization | 0.00% | 7.84% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.07% | -15.98% | |||
| Operating Income | 4.28% | -19.85% | |||
| Income Before Tax | -12.06% | -7.25% | |||
| Income Tax Expenses | 5.22% | -3.41% | |||
| Earnings from Continuing Operations | -16.56% | -8.20% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -16.56% | -8.20% | |||
| EBIT | 4.28% | -19.85% | |||
| EBITDA | 4.01% | -19.54% | |||
| EPS Basic | -13.70% | -7.47% | |||
| Normalized Basic EPS | 5.76% | -19.59% | |||
| EPS Diluted | -15.79% | -4.95% | |||
| Normalized Diluted EPS | 6.48% | -18.94% | |||
| Average Basic Shares Outstanding | -3.32% | -0.80% | |||
| Average Diluted Shares Outstanding | -4.01% | -1.60% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||